natgillin/translations-raw huggingface dataset:
EU/1/10/639/021 (14 tablets blister) EU/1/10/639/022 (28 tablets blister) EU/1/10/639/023 (30 tablets blister) EU/1/10/639/024 (56 tablets blister) EU/1/10/639/025 (84 tablets blister) EU/1/10/639/026 (90 tablets blister) EU/1/10/639/027 (98 tablets blister) EU/1/10/639/028 (100 tablets blister) 
EU/1/10/639/025 (blister s 84 tablete) EU/1/10/639/026 (blister s 90 tableta) EU/1/10/639/027 (blister s 98 tableta) EU/1/10/639/028 (blister sa 100 tableta)
Cardiac disorders Uncommon: 
Kardiovaskularna prevencija ONTARGET ispitivanje (eng.
Renal impairment including acute renal failure General disorders and administration site conditions Uncommon: Rare: 
Opći poremećaji i reakcije na mjestu primjene Manje često:
Teл. 
(tahikardija).
Back pain (e.g. sciatica), muscle spasms, myalgia Arthralgia, pain in extremity, tendor pain (tendinitis like symptoms) 
Artralgija, bol u ekstremitetima, bol tetiva (simptomi poput tendinitisa)
EU/1/10/639/001 (14 tablets blister) EU/1/10/639/002 (28 tablets blister) EU/1/10/639/003 (30 tablets blister) EU/1/10/639/004 (56 tablets blister) EU/1/10/639/005 (84 tablets blister) EU/1/10/639/006 (90 tablets blister) EU/1/10/639/007 (98 tablets blister) EU/1/10/639/008 (100 tablets blister) EU/1/10/639/009 (30 tablets container) EU/1/10/639/010 (250 tablets container) 
EU/1/10/639/001 (blister s 14 tableta) EU/1/10/639/002 (blister s 28 tableta) EU/1/10/639/003 (blister s 30 tableta) EU/1/10/639/004 (blister s 56 tableta)
Inventedname Strength Pharmaceutical Form 
(Zaštićeno) ime Jačina Farmaceutski oblik
EU number 
Brojevi (EU) odobrenja za stavljanje lijeka u promet
If you need more information about your animal's medical condition or treatment, contact your veterinarian. 
Ako trebate više informacija o zdravstvenom stanju ili liječenje svoje životinje, obratite se veterinaru.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease. 
Cjepiva djeluju „učeći” imunosni sustav (prirodna obrana tijela) kako se obraniti od bolesti.
They included young and adult cats of various breeds, but not young kittens. 
Ispitivanja su obuhvatila mlade i odrasle mačke različitih pasmina, ali ne i mlade mačiće.
This is a summary of the European public assessment report. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije.
The antibodies will help to protect against the diseases caused by these viruses. 
Protutijela pomažu u zaštiti od bolesti koje uzrokuju ti virusi.
The first injection should be given in kittens aged at least eight weeks, with a second injection three to four weeks later. 
Prvu injekciju treba dati mačićima u dobi od najmanje osam tjedana, a drugu injekciju tri do četiri tjedna kasnije.
The cat should be revaccinated for all components one year after the first vaccination course, then every three years. 
Potrebno je provesti revakcinaciju mačke za sve komponente godinu dana nakon prvog cijepljenja, a zatim svake tri godine.
When exposed to any of these viruses later in life, the cat will either not become infected or have a much less serious infection. 
Ako u budućnosti bude izložena nekom od tih virusa, mačka se neće zaraziti ili će imati mnogo blažu infekciju.
Information on the prescription status of this product may be found on the label/outer package. 
Informacije o tome je li za ovaj proizvod potreban recept možete naći na etiketi/vanjskom pakiranju.
The European Commission granted a marketing authorisation valid throughout the European Union for Purevax RC on 23 February 2005. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za VMP Purevax RC na snazi u Europskoj uniji od 23. veljače 2005.
If the kitten has high levels of antibodies received from the mother in the womb and in the milk, the first vaccination should be delayed until 12 weeks of age. 
Ako mačić ima visoke razine majčinih protutijela prenesenih u maternici i mlijekom, prvo cijepljenje trebalo bi odgoditi do dobi od 12 tjedana.
Purevax RC should not be used in pregnant cats. 
Purevax RC ne smije se primjenjivati u gravidnih mačaka.
The main measure of effectiveness was the level of antibodies in the blood against the viruses in the vaccine. 
Glavna mjera djelotvornosti bila je razina protutijela u krvi na viruse iz cjepiva.
Occasionally, cats will develop temporary apathy (loss of interest in surroundings) and anorexia (loss of appetite), as well as hyperthermia (elevated body temperature) lasting for one or two days. 
U mačaka se povremeno može javiti privremena apatija (gubitak interesa za okolinu) i anoreksija (gubitak apetita), kao i hipertermija (povišena tjelesna temperatura) koja traje jedan ili dva dana.
The vaccine helps to reduce the symptoms of the diseases and also helps to reduce viral excretion in case of calicivirus infection for one year after vaccination. 
Cjepivo pomaže u ublažavanju simptoma bolesti, kao i u smanjenju ekskrecije virusa u slučaju infekcije kalicivirusom tijekom jedne godine nakon cijepljenja.
There may be a local reaction at the injection site, with slight pain on touching, itching or oedema (swelling), which disappears within one or two weeks. 
Može se pojaviti i lokalna reakcija na mjestu injekcije u obliku lagane boli na dodir, svrbeža ili edema (otok), koja nestaje unutar jednog ili dva tjedna.
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses as ‘foreign' and makes antibodies against them. 
Kada mačka primi cjepivo, imunosni sustav prepoznaje oslabljene ili umrtvljene viruse kao „strana tijela” te protiv njih proizvodi protutijela.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Purevax RC exceed the risks for the approved indications and recommended that Purevax RC be given a marketing authorisation. 
Odbor za veterinarsko-medicinske proizvode (CVMP) zaključio je da koristi od VMP-a Purevax RC nadmašuju rizike za odobrene indikacije te je preporučio davanje odobrenja za stavljanje VMP-a Purevax RC u promet.
Purevax RC is used to vaccinate cats from the age of 8 weeks against: 
Purevax RC koristi se za cijepljenje mačaka starijih od osam tjedana protiv:
In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses. 
Nakon cijepljenja imunosni sustav može brže proizvoditi protutijela ako u budućnosti bude izložen stvarnim virusima.
• inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains). 
• inaktivirane (umrtvljene) antigene kalicivirusa (sojeve FCV 431 i G1).
In case of accidental self-injection medical advice should be sought immediately and the package leaflet or the label shown to the doctor. 
U slučaju nehotičnog samoinjektiranja treba odmah potražiti liječnički savjet te pokazati uputu o proizvodu ili etiketu.
Purevax RC is a veterinary vaccine that contains: 
Purevax RC je veterinarsko cjepivo koje sadrži:
The benefit-risk balance may be found in the scientific discussion module of this EPAR. 
Omjer koristi i rizika možete pronaći u modulu znanstvene rasprave ovog EPAR-a.
The effectiveness of Purevax RC has been studied in several trials in laboratory conditions where cats were vaccinated and infected with herpesvirus and calicivirus. 
Djelotvornost VMP-a Purevax RC ispitivana je u nekoliko ispitivanja u laboratorijskim uvjetima, u okviru kojih su mačke cijepljene i potom zaražene herpesvirusom i kalicivirusom.
In laboratory conditions Purevax RC was demonstrated to provide protection against the diseases listed above. 
U laboratorijskim uvjetima dokazano je da VMP Purevax RC pruža zaštitu od prethodno navedenih bolesti.
Purevax RC is available as a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection. 
Purevax RC dostupan je kao liofilizat (smrzavanjem osušen pelet) i otapalo od kojih se priprema suspenzija za injekciju.
Purevax RC contains small amounts of weakened or killed viruses that cause feline rhinotracheitis and calicivirosis. 
Purevax RC sadrži male količine oslabljenih ili umrtvljenih virusa koji uzrokuju rinotraheitis i kalicivirozu mačaka.
In the field, the studies of Purevax RC looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination. 
U ispitivanjima VMP-a Purevax RC na terenu razmatrao se osnovni raspored cijepljenja (dvije injekcije u razmaku od tri do četiri tjedna) te docjepljivanje.
• attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), 
• atenuirani (oslabljeni) herpesvirus rinotraheitisa mačaka (soj FHV F2),
Purevax RC is a vaccine. 
Purevax RC je cjepivo.
• feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus). 
• kaliciviroze mačaka (bolest nalik na gripu s upalom usta uzrokovana kalicivirusom).
Feline viral rhinotracheitis (live attenuated) and feline calicivirosis (inactivated) vaccine 
Cjepivo protiv virusnog rinotraheitisa (živo atenuirano) i kaliciviroze mačaka (inaktivirano)
What is the risk associated with Purevax RC? 
Koji su rizici povezani s VMP-om Purevax RC?
For a full list of the side-effects reported with Purevax RC, see the package leaflet. 
Potpuni popis svih nuspojava zabilježenih pri primjeni VMP-a Purevax RC potražite u uputi o VMP-u.
Why has Purevax RC been approved? 
Zašto je Purevax RC odobren?
In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus and calicivirus infection. 
U terenskom ispitivanju osnovnog cijepljenja zabilježen je porast protutijela na herpesvirus rinotraheitisa i kalicivirus u mačaka.
What is Purevax RC? 
Što je Purevax RC?
Other information about Purevax RC: 
Ostale informacije o VMP-u Purevax RC
What is Purevax RC used for? 
Za što se Purevax RC koristi?
• feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus), 
• virusnog rinotraheitisa mačaka (bolest nalik na gripu uzrokovana herpesvirusom),
What benefit has Purevax RC shown during the studies? 
Koje su koristi VMP-a Purevax RC utvrđene u ispitivanjima?
How does Purevax RC work? 
Kako djeluje Purevax RC?
In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus and calicivirus infection remained stable at a high level or increased slightly. 
U ispitivanju koje je promatralo docjepljivanje, zabilježena je stabilna visoka razina ili blagi porast protutijela na herpesvirus rinotraheitisa i kalicivirus.
How has Purevax RC been studied? 
Kako je VMP Purevax RC ispitivan?
15 micrograms HA** per 0.5 ml dose 
15 mikrograma HA** u dozama od 0,5 ml
Influenza virus surface antigens (haemagglutinin and neuraminidase)*, inactivated, of the following strains: A/California/7/2009 (H1N1)pdm09- like strain (A/Brisbane/10/2010, wild type) 
1 Površinski antigeni virusa gripe (hemaglutinin i neuraminidaza)*, inaktivirani, sljedećih sojeva: soj sličan A/California/7/2009 (H1N1)pdm09 - (divlji tip A/Brisbane/10/2010)
A/Switzerland/9715293/2013 (H3N2) - like strain (A/South Australia/55/2014, wild type) 
soj sličan A/Switzerland/9715293/2013 (H3N2) - (divlji tip A/South Australia/55/2014)
B/Phuket/3073/2013 - like strain (B/Utah/9/2014, wild type) 
soj sličan B/Phuket/3073/2013 - (divlji tip B/Utah/9/2014)
* propagated in Madin Darby Canine Kidney (MDCK) cells ** haemagglutinin 
* umnoženo u psećim renalnim stanicama Madin Darby (MDCK) ** hemaglutinin k i
Strength Pharmaceutical Form Route of Administration 
Doza Farmaceutski oblik Put primjene Unutarnje pakovanje Sastav (koncentracija)
2 x 10 pre-filled syringes (Luer Cone) + 20 needles 
2 x 10 štrcaljka s uloškom (Luer nastavak) + 20 igla
2 x 10 pre-filled syringes (Luer Lock) 
2 x 10 štrcaljka s uloškom (Luer Lock)
2 x 10 pre-filled syringes (Luer Cone) 
2 x 10 štrcaljka s uloškom (Luer nastavak)
EU numbers 
Sastav
Further information on Rhokiinsa can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rhokiinsa 
Više informacija o lijeku Rhokiinsa dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/rhokiinsa.
It is available as an eye-drop solution (200 microgram/ml) and the dose is one drop in the affected eye once a day, in the evening. 
Dostupan je kao otopina kapi za oči (200 mikrograma/ml), a doza je jedna kap u oboljelo oko jednom dnevno, navečer.
What is Rhokiinsa and what is it used for? 
Što je Rhokiinsa i za što se koristi?
What measures are being taken to ensure the safe and effective use of Rhokiinsa? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Rhokiinsa?
The European Medicines Agency therefore decided that Rhokiinsa's benefits are greater than its risks and it can be authorised for use in the EU. 
Europska agencija za lijekove stoga je zaključila da koristi od lijeka Rhokiinsa nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-u.
Side effects reported with Rhokiinsa are carefully evaluated and any necessary action taken to protect patients. 
Nuspojave prijavljene za lijek Rhokiinsa pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
In patients with moderately high eye pressure (up to 25 mmHg), Rhokiinsa was as effective as timolol (another medicine), lowering the pressure by around 3.9 mmHg to 4.7 mmHg, compared with reductions of 3.8 mmHg to 5.2 mmHg for patients using timolol. 
U bolesnika s umjereno visokim očnim tlakom (do 25 mmHg), lijek Rhokiinsa bio je jednako djelotvoran kao i timolol (drugi lijek) te je snizio tlak za oko 3,9 mmHg, tj. na 4,7 mmHg, u usporedbi sa smanjenjem od 3,8 mmHg, tj. na 5,2 mmHg u bolesnika koji su uzimali timolol.
However, when these results were combined with results from other studies, decreases in eye pressure with Rhokiinsa were larger than those seen in the main study only. 
Međutim, kada se ti rezultati kombiniraju s rezultatima iz drugih ispitivanja, smanjenja vrijednosti očnog tlaka s lijekom Rhokiinsa bila su veća od onih utvrđenih samo u glavnom ispitivanju.
When pressure in the eye is raised, it can cause damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain. 
Kada je očni tlak povišen, može doći do oštećenja retine (opne osjetljive na svjetlo koja se nalazi u stražnjem dijelu oka) i optičkog živca koji odašilje signale iz oka u mozak.
However, side effects on the eye were more frequent than those of timolol, and this may lead people to stop treatment. 
Međutim, nuspojave na oku bile su učestalije od nuspojava uzrokovanih timololom, što može navesti ljude da prestanu s liječenjem.
The safety of Rhokiinsa will be further investigated in a study. 
Sigurnost lijeka Rhokiinsa nastavit će se istraživati u ispitivanju.
Rhokiinsa, which has a different mode of action from previously authorised treatments, provides another treatment option for patients with open-angle glaucoma and ocular hypertension. 
Lijek Rhokiinsa, koji ima drugačiji način djelovanja od prethodno odobrenih lijekova, predstavlja dodatnu mogućnost liječenja za bolesnike s glaukomom otvorenog kuta i očnom hipertenzijom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rhokiinsa have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Rhokiinsa nalaze se u sažetku opisa svojstava i u uputi o lijeku.
Other information about Rhokiinsa 
Ostale informacije o lijeku Rhokiinsa
Other common side effects (which may affect up to 2 in 10 people) are: cornea verticillata (deposits in the cornea, the transparent layer in front of the eye that covers the pupil and iris), eye pain, conjunctival haemorrhage (bleeding in the surface layer of the eye), erythema (reddening) at the site where the medicine was applied and the eyelid, corneal staining, blurred vision and increased lacrimation (watery eyes). 
Ostale česte nuspojave (koje se mogu javiti u do 2 na 10 osoba) jesu: cornea verticillata (naslage u rožnici, prozirnom sloju u prednjem dijelu oka koji pokriva zjenicu i šarenicu), bol u oku, konjuktivno krvarenje (krvarenje u površinskom sloju oka), eritem (crvenilo) na mjestu primjene lijeka i na očnom kapku, obojanost rožnice, zamućen vid i povećana lakrimacija (suzne oči).
For more information about using Rhokiinsa, see the package leaflet or contact your doctor or pharmacist. 
Za više informacija o primjeni lijeka Rhokiinsa pročitajte uputu o lijeku odnosno obratite se liječniku ili ljekarniku.
This means that it blocks the activity of an enzyme called Rho kinase, which has a role in controlling drainage of fluid from the eye. 
To znači da inhibira djelovanje enzima Rho kinaze koji kontrolira istjecanje tekućine iz oka.
As for all medicines, data on the use of Rhokiinsa are continuously monitored. 
Kao i za sve lijekove, podatci o primjeni lijeka Rhokiinsa kontinuirano se prate.
An overview of Rhokiinsa and why it is authorised in the EU 
Pregled informacija o lijeku Rhokiinsa i zašto je odobren u EU-u
Why is Rhokiinsa authorised in the EU? 
Zašto je lijek Rhokiinsa odobren u EU-u?
Rhokiinsa is an eye-drop solution that is used to reduce pressure inside the eye in adults who have open-angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) or ocular hypertension (when the pressure in the eye is higher than normal). 
Rhokiinsa je otopina kapi za oči koja se koristi za smanjenje očnog tlaka u odraslih koji imaju glaukom otvorenog kuta (bolest kod koje tlak u oku raste zbog nemogućnosti istjecanja tekućine iz oka) ili očnu hipertenziju (kada je tlak u oku viši od normalnog).
The active substance in Rhokiinsa, netarsudil, is a Rho kinase inhibitor. 
Djelatna tvar u lijeku Rhokiinsa, netarsudil, inhibitor je Rho kinaze.
The most common side effect with Rhokiinsa (which may affect around 5 in 10 people) is conjunctival hyperaemia (increased blood supply to the eye, leading to redness). 
Najčešća nuspojava lijeka Rhokiinsa (koja se može javiti u otprilike 5 na 10 osoba) je konjuktivna hiperemija (povišen dotok krvi u oko što uzrokuje crvenilo).
A main study of 708 patients with open-angle glaucoma or ocular hypertension showed that Rhokiinsa is effective at lowering eye pressure. 
U glavnom ispitivanju na 708 bolesnika s glaukomom otvorenog kuta ili očnom hipertenzijom utvrđeno je da je lijek Rhokiinsa djelotvoran u snižavanju očnog tlaka.
In patients whose eye pressure was higher than 25 mmHg, Rhokiinsa was less effective than timolol. 
U bolesnika čiji je očni tlak bio veći od 25 mmHg, lijek Rhokiinsa bio je manje djelotvoran od timolola.
What are the risks associated with Rhokiinsa? 
Koji su rizici povezani s lijekom Rhokiinsa?
Rhokiinsa contains the active substance netarsudil. 
Lijek Rhokiinsa sadrži djelatnu tvar netarsudil.
The effect of Rhokiinsa was less pronounced in patients whose eye pressure was more than 30 mmHg, but these results were considered less important because Rhokiinsa is not expected to be used on its own in this group. 
Njegovo je djelovanje bilo manje naglašeno u bolesnika čiji je očni tlak iznosio preko 30 mmHg, ali ti su se podatci smatrali manje važnima jer se ne očekuje da će se lijek Rhokiinsa za tu skupinu bolesnika primjenjivati kao monoterapija.
In terms of safety, the side effects of Rhokiinsa are considered manageable and were more likely to be confined to the eye. 
Kada je riječ o sigurnosti, smatra se da je nuspojave lijeka Rhokiinsa moguće kontrolirati te da su vrlo vjerojatno ograničene na oko.
Rhokiinsa showed good effects across a range of eye pressures. 
Lijek Rhokiinsa pokazao se kao djelotvoran za različite vrste očnih tlakova.
Rhokiinsa is only available on prescription and should be started by an eye specialist. 
Lijek Rhokiinsa izdaje se samo na recept, a liječenje treba započeti specijalist oftalmolog.
How does Rhokiinsa work? 
Kako djeluje Rhokiinsa?
What benefits of Rhokiinsa have been shown in studies? 
Koje su koristi od lijeka Rhokiinsa utvrđene u ispitivanjima?
When it blocks this enzyme, Rhokiinsa increases the flow of fluid out of the eyeball, thereby lowering pressure inside the eye. Rhokiinsa is also thought to lower eye pressure by reducing pressure in the veins around the eyes. 
Kada lijek Rhokiinsa taj enzim ihhibira, povećava se istjecanje tekućine iz očne jabučice i time se smanjuje očni tlak.
For the full list of side effects and restrictions with Rhokiinsa, see the package leaflet. 
Potpuni popis nuspojava i ograničenja pri primjeni lijeka Rhokiinsa potražite u uputi o lijeku.
How is Rhokiinsa used? 
Kako se Rhokiinsa primjenjuje?
Packaging Content Package size 
Put primjene Pakiranje Sadržaj Veličina pakiranja
ATCvet code: QI06AJ03. 
ATCvet kod: QI06AJ03.
Date of first authorisation: 23/02/2005 Date of last renewal: 14/01/2010 
Datum prvog odobrenja: 23/02/2005 Datum posljednje obnove: 14/01/2010
Primary vaccination course: - first injection: from 8 weeks of age, - second injection: 3 to 4 weeks later. 
Prvo cijepljenje: - prva injekcija: od 8 tjedana starosti, - druga injekcija: 3 do 4 tjedna kasnije.
* less than 1 animal in 10,000 animals displaying adverse reaction(s) during the course of one treatment, including isolated reports. 
* manje od 1 životinje na 10.000 životinja pokazalo je nuspojave tijekom jedne primjene, uključujući izolirane slučajeve
EU/2/04/050/001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/050/002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml) 
EU/2/04/050/001 Liofilizat (10 bočica s 1 dozom) + otapalo (10 bočica od 1 ml) EU/2/04/050/002 Liofilizat (50 bočica s 1 dozom) + otapalo (50 bočica od 1 ml)
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals ) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 
Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 životinja pokazuju nuspojavu(e) za vrijeme trajanja tretmana) - česte (više od 1 ali manje od 10 životinja na 100 životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 životinja)
A local reaction may occur (slight pain at palpation, itching or limited oedema) that disappears within 1 or 2 weeks at most. 
Može se javiti i lokalna reakcija (lagana bol pri palpaciji, svrbež ili ograničena otok) koja nestaje za najviše 1 ili 2 tjedna.
Manufacturer responsible for the batch release: MERIAL 
Nositelj odobrenja za proizvodnju odgovoran za puštanje serije u promet: MERIAL
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis, panleucopenia or Chlamydophila components are expected to be present (e.g. in kittens of 9-12 weeks of age borne from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age. 
kaliciviroze, panleukopenije ili Chlamydophila (npr. kod mačića u dobi 9-12 tjedana porijeklom od mačaka cijepljenih prije graviditeta i/ili s poznatim ili suspektnim prethodnim izlaganjem patogenima, prvo cijepljenje treba odgoditi do dobi od 12 tjedana.
2 egg infective dose 50% 
2 količina virusa koja zarazi 50 posto oplođenih jaja u koja se virus ucijepi
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with Merial non-adjuvanted vaccine against feline leukaemia and/or administered the same day but not mixed with Merial adjuvanted vaccine against rabies. 
Dostupni su podaci o neškodljivosti i učinkovitosti koji pokazuju da se ova vakcina može miješati i primijeniti s Merialovom vakcinom protiv mačje leukemije i/ili primijeniti isti dan, ali se ne smije miješati s Merialovom vakcinom protiv bjesnoće.